{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T10:44:34Z","timestamp":1763117074206,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS105853","R01 NS105853","R01 NS105853","R01 NS105853","R01 NS105853","R01 NS105853","R01 NS105853"],"award-info":[{"award-number":["R01 NS105853","R01 NS105853","R01 NS105853","R01 NS105853","R01 NS105853","R01 NS105853","R01 NS105853"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The risk of acute ischemic stroke (AIS) associated with high estrogen states, including pregnant patients and those using oral contraceptives, has been well documented. We described the histological composition of thrombi collected in these cases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>From a prospective tissue registry (STRIP registry) of thrombi retrieved during mechanical thrombectomy for AIS, we identified 5 patients with high estrogen states: 1 post-partum patient, 1 undergoing hormone replacement therapy and 3 consuming oral contraceptive pills. Five male control patients were randomly chosen matched by age. Immunohistochemistry for CD42b (platelets), von Willebrand factor (vWF), thrombin-activatable fibrinolysis inhibitor (TAFI), fibrinogen and plasminogen activator inhibitor-1 (PAI-1) was performed. Expression was quantified using Orbit Image Software. Student\u2019s t-test was performed as appropriate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mean TAFI content for the high estrogen state group was higher than controls (25.6\u2009\u00b1\u200911.9% versus 9.3\u2009\u00b1\u20099.0%, <jats:italic>p<\/jats:italic>\u2009=\u20090.043*). Mean platelet content for the high estrogen state group was lower than controls (41.7\u2009\u00b1\u200910.6% versus 61.8\u2009\u00b1\u200912.9%, <jats:italic>p<\/jats:italic>\u2009=\u20090.029*). No significant difference was found in vWF, fibrinogen and PAI-1 expression. Mean time to recanalize was higher in the high estrogen state group compared to the control group (57.8\u2009\u00b1\u200927.6 versus 22.6\u2009\u00b1\u200911.4\u00a0min, <jats:italic>p<\/jats:italic>\u2009=\u20090.0351*). The mean number of passes required was higher in the high estrogen group compared to controls 4.6 versus 1.2, <jats:italic>p<\/jats:italic>\u2009=\u20090.0261*).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>TAFI expression, a powerful driver of thrombosis, was significantly higher in stroke thrombi among patients with high estrogen states compared to controls.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-024-03579-2","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T05:01:28Z","timestamp":1709787688000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High thrombin-activatable fibrinolysis inhibitor expression in thrombi from stroke patients in elevated estrogen states"],"prefix":"10.1186","volume":"24","author":[{"given":"Tamanna","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oana Madalina","family":"Mereuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherief","family":"Ghozy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge L Arturo","family":"Larco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cem","family":"Bilgin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram","family":"Kadirvel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waleed","family":"Brinjikji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David F","family":"Kallmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"3579_CR1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1161\/hq0202.102318","volume":"22","author":"F r Rosendaal","year":"2002","unstructured":"Rosendaal F r., Helmerhorst F m., Vandenbroucke J p. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol. 2002;22:201\u201310.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3579_CR2","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1056\/NEJMoa1111840","volume":"366","author":"\u00d8 Lidegaard","year":"2012","unstructured":"Lidegaard \u00d8, L\u00f8kkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366:2257\u201366.","journal-title":"N Engl J Med"},{"key":"3579_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11154-011-9178-0","volume":"12","author":"TG DeLoughery","year":"2011","unstructured":"DeLoughery TG. Estrogen and thrombosis: controversies and common sense. Rev Endocr Metab Disord. 2011;12:77\u201384.","journal-title":"Rev Endocr Metab Disord"},{"key":"3579_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.thromres.2020.05.008","volume":"192","author":"MY Abou-Ismail","year":"2020","unstructured":"Abou-Ismail MY, Citla Sridhar D, Nayak L. Estrogen and thrombosis: a bench to bedside review. Thromb Res. 2020;192:40\u201351.","journal-title":"Thromb Res"},{"key":"3579_CR5","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood-2003-04-1285","volume":"103","author":"JM Kemmeren","year":"2004","unstructured":"Kemmeren JM, Algra A, Meijers JCM, Tans G, Bouma BN, Curvers J, Rosing J, Grobbee DE. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. Blood. 2004;103:927\u201333.","journal-title":"Blood"},{"key":"3579_CR6","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1111\/j.1538-7836.2005.01484.x","volume":"3","author":"FWG Leebeek","year":"2005","unstructured":"Leebeek FWG, Goor MPJ, Guimaraes AHC, Brouwers G-J, Maat MPM, Dippel DWJ, Rijken DC. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost JTH. 2005;3:2211\u20138.","journal-title":"J Thromb Haemost JTH"},{"key":"3579_CR7","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1161\/01.STR.0000088642.07691.15","volume":"34","author":"A Santamar\u00eda","year":"2003","unstructured":"Santamar\u00eda A, Oliver A, Borrell M, Mateo J, Belvis R, Mart\u00ed-F\u00e1bregas J, Ort\u00edn R, Tirado I, Souto JC, Fontcuberta J. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke. 2003;34:2387\u201391.","journal-title":"Stroke"},{"key":"3579_CR8","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1161\/01.STR.0000063139.06585.45","volume":"34","author":"J Montaner","year":"2003","unstructured":"Montaner J, Rib\u00f3 M, Monasterio J, Molina CA, Alvarez-Sab\u00edn J. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke. 2003;34:1038\u201340.","journal-title":"Stroke"},{"key":"3579_CR9","doi-asserted-by":"publisher","first-page":"e0225841","DOI":"10.1371\/journal.pone.0225841","volume":"14","author":"S Fitzgerald","year":"2019","unstructured":"Fitzgerald S, Wang S, Dai D Jr, Pandit DHM, Douglas A, Rizvi A, Kadirvel A, Gilvarry R, McCarthy M, Stritt R, Gounis M, Brinjikji MJ, Kallmes W, Doyle DF. Orbit image analysis machine learning software can be used for the histological quantification of acute ischemic stroke blood clots. PLoS ONE. 2019;14:e0225841.","journal-title":"PLoS ONE"},{"key":"3579_CR10","doi-asserted-by":"publisher","first-page":"e1007313","DOI":"10.1371\/journal.pcbi.1007313","volume":"16","author":"M Stritt","year":"2020","unstructured":"Stritt M, Stalder AK, Vezzali E. Orbit image analysis: an open-source whole slide image analysis tool. PLOS Comput Biol. 2020;16:e1007313.","journal-title":"PLOS Comput Biol"},{"key":"3579_CR11","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1111\/j.1538-7836.2007.02665.x","volume":"5","author":"I Fernandez-Cadenas","year":"2007","unstructured":"Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M, Rubiera M, Mendioroz M, Molina CA, Rosell A, Montaner J. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients. J Thromb Haemost JTH. 2007;5:1862\u20138.","journal-title":"J Thromb Haemost JTH"},{"key":"3579_CR12","doi-asserted-by":"publisher","first-page":"27176","DOI":"10.1074\/jbc.273.42.27176","volume":"273","author":"W Wang","year":"1998","unstructured":"Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1998;273:27176\u201381.","journal-title":"J Biol Chem"},{"key":"3579_CR13","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1161\/01.ATV.20.9.2156","volume":"20","author":"I Juhan-Vague","year":"2000","unstructured":"Juhan-Vague I, Renucci JF, Grimaux M, Morange PE, Gouvernet J, Gourmelin Y, Alessi MC. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2000;20:2156\u201361.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3579_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0037-1613959","volume":"84","author":"JC Meijers","year":"2000","unstructured":"Meijers JC, Middeldorp S, Tekelenburg W, van den Ende AE, Tans G, Prins MH, Rosing J, B\u00fcller HR, Bouma BN. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost. 2000;84:9\u201314.","journal-title":"Thromb Haemost"},{"key":"3579_CR15","doi-asserted-by":"publisher","first-page":"4844","DOI":"10.1182\/blood-2002-09-2944","volume":"101","author":"LO Mosnier","year":"2003","unstructured":"Mosnier LO, Buijtenhuijs P, Marx PF, Meijers JCM, Bouma BN. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood. 2003;101:4844\u20136.","journal-title":"Blood"},{"key":"3579_CR16","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1182\/bloodadvances.2020002923","volume":"4","author":"Y Suzuki","year":"2020","unstructured":"Suzuki Y, Sano H, Mochizuki L, Honkura N, Urano T. Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system. Blood Adv. 2020;4:5501\u201311.","journal-title":"Blood Adv"},{"key":"3579_CR17","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1160\/TH04-06-0387","volume":"92","author":"HA Mousa","year":"2004","unstructured":"Mousa HA, Downey C, Alfirevic Z, Toh C-H. Thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy. Thromb Haemost. 2004;92:1025\u201331.","journal-title":"Thromb Haemost"},{"key":"3579_CR18","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.3390\/ijms20123111","volume":"20","author":"M Dupuis","year":"2019","unstructured":"Dupuis M, Severin S, Noirrit-Esclassan E, Arnal J-F, Payrastre B, Val\u00e9ra M-C. Effects of estrogens on platelets and megakaryocytes. Int J Mol Sci. 2019;20:3111.","journal-title":"Int J Mol Sci"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03579-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-024-03579-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03579-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T05:02:31Z","timestamp":1709787751000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-024-03579-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3579"],"URL":"https:\/\/doi.org\/10.1186\/s12883-024-03579-2","relation":{},"ISSN":["1471-2377"],"issn-type":[{"type":"electronic","value":"1471-2377"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"assertion":[{"value":"27 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved and waiver of consent was granted by the Institutional Review Board at Mayo Clinic (Rochester, Minnesota): IRB 16-001131.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"RK received research support from Cerenovus Inc, Medtronic, Endovascular Engineering, Frontier Bio, Sensome Inc, Endomimetics, Ancure LLC, Neurogami Medical, MIVI Biosciences, Monarch Biosciences, Stryker Inc, Conway Medical, Piraeus Medical, Bionaut Labs. WB holds equity in Nested Knowledge, Superior Medical Editors, Piraeus Medical, Sonoris Medical, and MIVI Neurovascular; he receives royalties from Medtronic and Balloon Guide Catheter Technology; he receives consulting fees from Medtronic, Stryker, Imperative Care, Microvention, MIVI Neurovascular, Cerenovus, Asahi, and Balt; he serves in a leadership or fiduciary role for MIVI Neurovascular, Marblehead Medical LLC, Interventional Neuroradiology (editor in chief), Piraeus Medical, and WFITN. DFK holds equity in Nested Knowledge, Superior Medical Experts, and Conway Medical, Marblehead Medical, and Piraeus Medical; he receives grant support from MicroVention, Medtronic, Balt, and Insera Therapeutics; has served on the Data Safety Monitoring Board for Vesalio; and received royalties from Medtronic. TA, OMM, SG, JLA and CB have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}